GSK plc stock (NYSE: GSK) trades at $38 per share, about 20% below its peak level of over $47 seen in April 2022.

For new and old investors, taking full advantage of the stock market and investing ... its share price will decline as well. Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, ...

GlaxoSmithKline Is Moving Forward After Woeful Performance Jul. 08, 2014 5:27 PM ET GSK plc (GSK) Stock AZN, MRK, NVS PFE INVA GSK 8 Comments Options Calling 480 Follower s ...

Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its sales and profits to improve.

GSK is demonstrating strong operating performance and expects record sales for Shingrix this year. See why I rate GSK stock a strong buy.

GlaxoSmithKline Plc GSK Q1 revenue fell 18% in the first quarter, as the COVID-19 vaccination program delayed sales of its Shingrix shot for shingles.

European stocks ended the week with a small decline, as GSK Plc’s shares weighed on the healthcare sector on a busy earnings day.

GSK's Q4 sales hit $10.40 billion, topping estimates. Specialty Medicines grew 14%, while vaccines declined. The company announced a $2.5 billion share buyback plan.

GSK plc stock (NYSE: GSK) trades at $38 per share, about 20% below its peak level of over $47 seen in April 2022. In contrast, its peer Bristol Myers Squibb stock (NYSE: BMY) saw a 48% decline ...

GSK (GSK) closed at $37.56 in the latest trading session, marking a +0.59% move from the prior day. The stock outperformed the S&P 500, which registered a daily gain of 0.43%. On the other hand ...